Organigram Global Inc. (OGI) sets Feb. 10 call for Q1 2026 results

Rhea-AI Filing Summary

Organigram Global Inc. will report its first quarter fiscal 2026 results, for the period ended December 31, 2025, on Tuesday, February 10, 2026, before the market opens. The company will host a conference call that day at 8:00 a.m. Eastern Time for investors and analysts.

Participants must register online to receive personalized dial-in details and access codes, and a live webcast will also be available. A replay of the webcast will be posted on Organigram’s investor website within 24 hours and remain accessible for 90 days. The filing also reiterates the company’s cannabis-focused operations in Canada and includes standard forward-looking statement cautions.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-38885

ORGANIGRAM GLOBAL INC.

(Translation of registrant’s name into English)

145 King Street West, Suite 1400

Toronto, Ontario ,Canada M5H 1J8

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ]           Form 40-F [ X ]

SUBMITTED HEREWITH

Exhibits

99.1 News Release dated February 3, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORGANIGRAM GLOBAL INC.

/s/ Greg Guyatt

Greg Guyatt

Chief Financial Officer

Date: February 3, 2026

Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

TORONTO--(BUSINESS WIRE)-- February 3, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. 

The Company will host a conference call to discuss its results with details as follows: 

Date: Tuesday, February 10, 2026

Time: 8:00 am Eastern Time 

To register for the conference call, please use this link: 

https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call. 

To access the webcast: 

https://events.q4inc.com/attendee/430252525

Participants will receive their details via email. 

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call. 

About Organigram

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Collective Project Limited, Organigram Global participates in the US and Canadian cannabinoid beverages markets.

Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O’ Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for

labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.

Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information including expectations regarding market performance, involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram Global to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis, and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations

investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Global Brands and Corporate Affairs

megan.mccrae@organigram.ca

FAQ

When will Organigram Global Inc. (OGI) report Q1 fiscal 2026 results?

Organigram will report its first quarter fiscal 2026 results on Tuesday, February 10, 2026, before market open. The results cover the quarter ended December 31, 2025, and will be accompanied by a conference call for investors and analysts.

What time is Organigram Global Inc. (OGI)’s Q1 2026 earnings conference call?

The Q1 fiscal 2026 conference call is scheduled for 8:00 a.m. Eastern Time on Tuesday, February 10, 2026. Participants can join by registering through the provided online link, which will supply dial-in details and unique access codes.

How can investors register for Organigram (OGI)’s Q1 2026 earnings call?

Investors can register using the specified online registration link in the announcement. After registering, they receive an email with dial-in information and unique conference codes. Registration is recommended at least 10 minutes before the call and remains open through the live event.

Will a replay of Organigram (OGI)’s Q1 2026 earnings webcast be available?

Yes. A replay of the earnings webcast will be available within 24 hours after the call concludes. It will be accessible through Organigram’s investor relations website and will remain archived for a period of 90 days following the event.

What businesses and brands does Organigram Global Inc. (OGI) operate?

Organigram operates cannabis cultivation and processing through Organigram Inc. and participates in cannabinoid beverages via Collective Project Limited. It has brands including Edison, SHRED, Big Bag O’ Buds, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK across Canada.

Where are Organigram Global Inc. (OGI)’s main facilities located?

Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, plus an edibles manufacturing facility in Winnipeg, Manitoba. It also runs cannabis processing facilities in Aylmer and London, Southwestern Ontario, focused on extraction, formulation, packaging and national fulfillment.

What forward-looking statement cautions does Organigram (OGI) highlight?

Organigram notes that forward-looking information involves risks and uncertainties that may cause actual results to differ materially. It points readers to its annual information form, management’s discussion and analysis, and other filings on SEDAR+ and EDGAR for detailed risk disclosures.